bioRxiv Science⌕ Search

Biology subjects

Kalteis, M. S.

Publications and source records attributed to Kalteis, M. S..

2 recordsLinked to original sources

An organotypic in vitro model of human papillomavirus-associated precancerous lesions allowing automated cell quantification for preclinical drug testing

Summary and graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=176 SRC="FIGDIR/small/661539v1_ufig1.gif" ALT="Figure 1"> View larger version (69K): org.highwire.dtl.DTLVardef@11e0c27org.highwire.dtl.DTLVardef@1affaf8org.highwire.dtl.DTLVardef@85c10forg.highwire.dtl.DTLVardef@145d491_HPS_FORMAT_FIGEXP M_FIG C_FIG O_LIA durable organotypic epithelial raft culture was established as a model of cervical precancer. C_LIO_LIPlausible time- and dose-dependent effects of cisplatin, 5-FU, and sinecatechins treatment were observed on keratinocytes and HPV-transformed cells. C_LIO_LITreatment effects were reliably quantified using machine learning-based cell classification. C_LIO_LIThis model may serve as a platform for preclinical investigation of topical and systemic treatment. C_LI Oncogenic human papillomaviruses (HPV) are causally responsible for invasive cancers and precancerous lesions. These lesions represent a considerable disease burden worldwide, yet no causally effective treatments are available. The development of HPV tumor models realistically reflecting the in vivo treatment situation is necessary for finding new effective and tissue-sparing treatments. This study aimed to establish an in vitro model of HPV-induced precancerous lesions for preclinical drug testing and to provide an automated method for quantifying cell counts to assess treatment effects in this model. To establish organotypic epithelial raft cultures (OTCs) as a model of HPV-induced precancerous lesions, we cultivated HPV-transformed cervical cancer cell lines SiHa, CaSki, HeLa, and SW756 in conjunction with primary human keratinocytes on a dermal equivalent and evaluated the impact of different cultivation variables. To demonstrate suitability of our model for preclinical drug application studies, we applied 5-fluorouracil, sinecatechins, and cisplatin either onto the air-exposed surface or to the growth medium, mimicking topical and systemic drug administration routes. We then developed a machine learning-based approach to quantify cell counts reflecting treatment effects in the established OTCs. We successfully optimized a durable in vitro model of HPV-induced precancerous lesions. The model enabled monitoring of treatment effects in a three-dimensional context with differentiated consideration of the targeted HPV-transformed cells and surrounding normal epithelium. We demonstrated that extreme gradient boosted tree classifiers (XGBoost) can be successfully used to distinguish the number of tumor cells, normal keratinocytes, and degraded cells with high accuracy (81.8{+/-}8%; P=2x10-6). Critically, quantification results plausibly reflected microscopical observations and gave a fine-grained picture of time- and dose-dependent treatment effects. The established model in combination with automated cell quantification can serve as a valuable tool in analyzing major preclinical endpoints in in vitro studies, such as target cell treatment efficacy, potential side effects, and treatment schedule optimization.

cancer biology↗

The shared neoantigen landscape of MSI cancers reflects immunoediting during tumor evolution

The immune system can recognize and attack cancer cells, especially those with a high load of mutation-induced neoantigens. Such neoantigens are particularly abundant in DNA mismatch repair (MMR)-deficient, microsatellite-unstable (MSI) cancers. MMR deficiency leads to insertion/deletion (indel) mutations at coding microsatellites (cMS) and to neoantigen-inducing translational frameshifts. The abundance of mutational neoantigens renders MSI cancers sensitive to immune checkpoint blockade. However, the neoantigen landscape of MMR-deficient cancers has not yet been systematically mapped. In the present study, we used a novel tool to monitor neoantigen-inducing indel mutations in MSI colorectal and endometrial cancer. Our results show that MSI cancers share several highly immunogenic neoantigens that result from specific, recurrent indel mutation events. Notably, the frequency of such indel mutations was negatively correlated to the predicted immunogenicity of the resulting neoantigens. These observations suggest continuous immunoediting of emerging MMR-deficient cells during tumor evolution.\n\nOne sentence summaryQuantitative indel mutation analysis reveals evidence of immune selection in mismatch repair-deficient cancers

cancer biology↗